PA
ORKA

Perceptive Advisors’s Oruka Therapeutics ORKA Stock Holding History

Perceptive Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128M Sell
1,345,063
-50,438
-4% -$3.36M 1.92% 15
2026
Q1 		$68.4M Sell
1,395,501
-81,000
-5% -$2.82M 1.34% 22
2025
Q4 		$44.8M Buy
1,476,501
+208,480
+16% +$5.81M 0.8% 39
2025
Q3 		$24.4M Buy
+1,268,021
New +$18.8M 0.7% 41
2025
Q1 		– Sell
-845,567
Closed -$16.4M – 111
2024
Q4 		$16.4M Sell
845,567
-389,620
-32% -$9.5M 0.45% 46
2024
Q3 		$30.3M Buy
+1,235,187
New +$43M 0.64% 39

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Perceptive Advisors's ORKA Position: Q2 2026 in Review

Perceptive Advisors reduced its Oruka Therapeutics (ORKA) stake by 3.6% in Q2 2026, selling an estimated $3.36M and leaving 1,345,063 shares worth $128M. The position accounts for 1.92% of the portfolio, ranked #15.

Perceptive Advisors first reported a position in ORKA in Q3 2024 and has held it in 6 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Perceptive Advisors held 1,345,063 shares of Oruka Therapeutics worth $128M as of Q2 2026.
  • Perceptive Advisors sold 50,438 Oruka Therapeutics shares in Q2 2026, an estimated $3.36M.
  • Oruka Therapeutics made up 1.92% of Perceptive Advisors's portfolio in Q2 2026, its #15 holding.
  • Perceptive Advisors first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.